Accessibility Menu
Kymera Therapeutics logo

Kymera Therapeutics

(NASDAQ) KYMR

Current Price$73.20
Market Cap$6.02B
Since IPO (2020)+120%
5 Year+53%
1 Year+68%
1 Month-12%

Kymera Therapeutics Financials at a Glance

Market Cap

$6.02B

Revenue (TTM)

$51.47M

Net Income (TTM)

-$315.05M

EPS (TTM)

-$3.57

P/E Ratio

-20.50

Dividend

$0.00

Beta (Volatility)

1.65 (High)

Price

$73.20

Volume

860,563.645

Open

$70.98

Previous Close

$73.21

Daily Range

$69.48 - $73.94

52-Week Range

$36.65 - $103.00

KYMR: Motley Fool Moneyball Superscore

60

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Kymera Therapeutics

Industry

Biotechnology

Employees

238

CEO

Nello Mainolfi, PhD

Headquarters

Watertown, MA 02472, US

KYMR Financials

Key Financial Metrics (TTM)

Gross Margin

100%

Operating Margin

-7%

Net Income Margin

-6%

Return on Equity

-27%

Return on Capital

-22%

Return on Assets

-19%

Earnings Yield

-4.88%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$6.02B

Shares Outstanding

82.26M

Volume

860.56K

Avg. Volume

575.18K

Financials (TTM)

Gross Profit

$39.20M

Operating Income

-$349.40M

EBITDA

-$303.06M

Operating Cash Flow

-$232.89M

Capital Expenditure

-$1.45M

Free Cash Flow

-$234.34M

Cash & ST Invst.

$848.28M

Total Debt

$82.25M

Kymera Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$34.37M

+55.5%

Gross Profit

$34.37M

+55.5%

Gross Margin

100.00%

N/A

Market Cap

$6.02B

N/A

Market Cap/Employee

$28.95M

N/A

Employees

208

N/A

Net Income

-$69.23M

-5.6%

EBITDA

-$67.15M

-5.8%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Net Cash

$570.46M

+51.4%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$66.74M

-8.7%

Short Term Debt

$13.73M

+3.7%

Return on Assets

-18.88%

N/A

Return on Invested Capital

-22.36%

N/A

Free Cash Flow

-$89.27M

-12.1%

Operating Cash Flow

-$88.84M

-12.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PRAXPraxis Precision Medicines, Inc.
$278.93+8.08%
IMVTImmunovant, Inc.
$31.15+0.74%
ACLXArcellx, Inc.
$115.07+0.02%
AKROAkero Therapeutics, Inc.
$54.65+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$16.73-0.01%
NVTSNavitas Semiconductor
$30.84+0.19%
XOSXos
$7.46+2.35%
BBBlackBerry
$10.18-0.01%

Questions About KYMR

What is the current price of Kymera Therapeutics?

Kymera Therapeutics is trading at $73.21 per share.

What is the 52-week range for Kymera Therapeutics?

Over the past 52 weeks, Kymera Therapeutics has traded between $36.65 and $103.00.

How much debt does Kymera Therapeutics have?

As of the most recent reporting period, Kymera Therapeutics reported total debt of $80.47M.

How much cash does Kymera Therapeutics have on hand?

Kymera Therapeutics reported $144.09M in cash and cash equivalents in its most recent financial results.

What is Kymera Therapeutics’s dividend yield?

Kymera Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.